Related Experiment Videos
Clinical aspects of sentinel node biopsy.
1The Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, New York 10021, USA. codyh@mskcc.org
Breast Cancer Research : BCR
|March 16, 2001
Summary
Sentinel lymph node (SLN) biopsy is a valuable technique for breast cancer staging. Achieving high success rates and low false negative results is crucial for its adoption in clinical practice.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Sentinel lymph node (SLN) biopsy requires validation before widespread adoption.
- Establishing success rates and false negative rates is essential for surgeons and institutions.
- Current practice involves backup axillary dissection for validation.
Purpose of the Study:
- To evaluate the feasibility and accuracy of SLN biopsy in breast cancer staging.
- To define success metrics for SLN biopsy implementation.
- To explore the role of SLN biopsy in various breast cancer scenarios.
Main Methods:
- Combination of isotope and dye for SLN mapping.
- Analysis of clinical stage T1-2N0 invasive breast cancers.
- Evaluation of SLN biopsy in prophylactic mastectomy and high-risk cases.
Main Results:
- A success rate of at least 90% with 5-10% false negative results is a reasonable goal.
- Technical variations yield similar results, suggesting procedural robustness.
- SLN biopsy is suitable for most breast cancer patients, particularly those with early-stage disease.
Conclusions:
- SLN biopsy offers enhanced pathologic analysis, improving staging accuracy and reducing morbidity.
- Micrometastases detected via SLN biopsy may have prognostic significance.
- Prospective trials are needed to confirm the prognostic value of micrometastases.